Interview with Dr. Evangelia Razis

Dr Evangelia Razis breast cancer

Share This Post

We had the pleasure of interviewing Dr. Evangelia Razis, oncologic medical professional and member of the Executive Board at Breast International Group. Dr. Razis shared her perspectives on the future of breast cancer research and the critical role played by BIG.

—-

Could you please explain what motivated you to serve on the BIG Executive Board (EB)?

I’ve always admired BIG’s global potential to do purely academic breast cancer research, and the fact that as an organisation it values scientific research, focused on the needs of the patients and society as a whole.

What are your personal goals and aspirations as a member of the executive board at BIG?

I joined the board aspiring to contribute to BIG’s strategy, from both the perspective of my southern European country, as well as from my experience from volunteering throughout the world. Additionally, because of my focus in Neurooncology, I hope to promote research in the area of Central Nervous System (CNS) metastasis from breast cancer.

Please cite three elements that you find critical for the continued success of BIG in the next decade?

  1. Vigilance in sensing the changes in the field of cancer research and the ability to adapt to novel approaches, (AI, real word data etc).
  2. Fundraising that comes from independent sources that will allow for the continuation of independent academic research.
  3. Identification of niche fields, where global collaboration is critical for the conduct of relevant research.

What values do you believe are essential to ensure a positive and successful future for BIG?

  • The focus in sustainable approaches to cancer treatment and prevention.
  • Interest in translational research that leads to better understanding of carcinogenesis and cancer progression at a molecular level.
  • Maintenance of an approach that remains independent of industry.

What are the biggest challenges currently faced by all stakeholders of the breast cancer research area? How do you think BIG can play a significant role in this context?

The biology of breast cancer is extremely complex. BIG’s ability to accrue large numbers of patients allows for the exploration of the intricacies of different subtypes.
The cost of both the research itself and the new systemic therapy agents to society is too high to support. Any study that leads to de-escalation is very important. BIG is able to conduct independent research and therefore can investigate options of de-escalation, which are of extremely important societal value.

Do you think we will see practice-changing results from breast cancer research in the next decade? Which ones?

  • Increased use of nonchemotherapy containing regimens particularly in HER2- positive disease.
  • De-escalation of both local and systemic therapy in early disease.
  • Treatment of subtypes of triple negative breast cancer with targeted therapy.

More to explore